TABLE OF CONTENTS
1 INTRODUCTION 44
1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF THE GLOBAL COLORECTAL CANCER DIAGNOSTICS MARKET 44
1.4 LIMITATIONS 46
1.5 MARKETS COVERED 46
2 MARKET SEGMENTATION 49
2.1 MARKETS COVERED 49
2.2 GEOGRAPHICAL SCOPE 50
2.3 YEARS CONSIDERED FOR THE STUDY 51
2.4 CURRENCY AND PRICING 51
2.5 DBMR TRIPOD DATA VALIDATION MODEL 52
2.6 MULTIVARIATE MODELLING 55
2.7 PRODUCT TYPE LIFELINE CURVE 55
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
2.9 DBMR MARKET POSITION GRID 57
2.10 MARKET END USER COVERAGE GRID 58
2.11 VENDOR SHARE ANALYSIS 59
2.12 SECONDARY SOURCES 60
2.13 ASSUMPTIONS 60
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 64
4.1 PORTERS FIVE FORCES 67
4.2 PESTEL ANALYSIS 68
5 INDUSTRY INSIGHTS: 69
6 GLOBAL COLORECTAL CANCER DIAGNOSTICS MARKET, REGULATIONS 70
6.1 REGULATORY SCENARIO IN THE U.S 70
6.2 REGULATORY SCENARIO IN AUSTRALIA 70
6.3 REGULATORY SCENARIO IN JAPAN 71
6.4 REGULATORY SCENARIO IN CHINA 71
7 MARKET OVERVIEW 73
7.1 DRIVERS 75
7.1.1 GROWING PREVALENCE OF COLORECTAL CANCER 75
7.1.2 RISE IN THE NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS. 75
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 75
7.2 RESTRAINTS 76
7.2.1 STRINGENT REGULATORY POLICIES 76
7.2.2 HIGH COST FOR THE COLORECTAL CANCER TREATMENTS. 76
7.3 OPPORTUNITIES 77
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 77
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 78
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 78
7.4 CHALLENGES 79
7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 79
7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 80
8 GLOBAL COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 81
8.1 OVERVIEW 82
8.2 INSTRUMENTS 85
8.2.1 PATHOLOGY-BASED INSTRUMENTS 86
8.2.1.1 PCR INSTRUMENTS 86
8.2.1.2 SLIDE STAINING SYSTEMS 86
8.2.1.3 TISSUE PROCESSING SYSTEMS 87
8.2.1.4 CELL PROCESSORS 87
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 87
8.2.2 IMAGING INSTRUMENTS 87
8.2.2.1 ULTRASOUND SYSTEMS 87
8.2.2.2 CT SYSTEMS 87
8.2.2.3 MRI SYSTEMS 88
8.2.2.4 OTHERS 88
8.2.3 BIOPSY INSTRUMENTS 88
8.2.4 OTHERS 88
8.3 CONSUMABLES & ACCESSORIES 88
8.3.1 KITS 89
8.3.1.1 PCR KITS 89
8.3.1.2 DNA POLYMERASE KITS 89
8.3.1.3 NUCLEIC ACID ISOLATION KITS 89
8.3.1.4 OTHERS 90
8.3.2 REAGENTS 90
8.3.2.1 ASSAYS 90
8.3.2.2 BUFFERS 90
8.3.2.3 PRIMERS 90
8.3.2.4 OTHERS 90
8.3.3 OTHER CONSUMABLES 90
9 GLOBAL COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE 91
9.1 OVERVIEW 92
9.2 STOOL EXAMINATION 95
9.3 BLOOD TEST 95
9.3.1 COMPLETE BLOOD COUNT (CBC) 96
9.3.2 TUMOR MARKER TEST 97
9.3.3 LIVER ENZYME BLOOD TEST 97
9.4 IMAGING TEST 97
9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 98
9.4.2 MRI 98
9.4.3 ULTRASOUND 98
9.4.4 POSITION EMISSION TOMOGRAPHY (PET) 99
9.4.5 OTHERS 99
9.5 TUMOR MARKERS 99
9.5.1 CARCINOEMBRYONIC ANTIGEN (CEA) 100
9.5.2 CA19-9 BIOMARKER TEST 100
9.5.3 CA 50 MARKER TEST 100
9.5.4 OTHERS 100
9.6 BIOPSY 100
9.7 OTHERS 101
10 GLOBAL COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 102
10.1 OVERVIEW 103
10.2 STAGE III 106
10.3 STAGE IV 106
10.4 STAGE II 107
10.5 STAGE I 108
10.6 STAGE 0 108
11 GLOBAL COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP 110
11.1 OVERVIEW 111
11.2 GERIATRIC 114
11.3 ADULTS 114
11.4 PEDIATRIC 115
12 GLOBAL COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 117
12.1 OVERVIEW 118
12.2 ADENOCARCINOMA 121
12.3 COLORECTAL LYMPHOMA 121
12.4 GASTROINTESTINAL STROMAL TUMORS 122
12.5 CARCINOID TUMORS 123
12.6 OTHERS 123
13 GLOBAL COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER 125
13.1 OVERVIEW 126
13.2 HOSPITALS 129
13.3 DIAGNOSTIC CENTERS 129
13.4 CANCER RESEARCH CENTERS 130
13.5 AMBULATORY SURGICAL CENTERS 131
13.6 ACADEMIC INSTITUTES 131
13.7 OTHERS 132
14 GLOBAL COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION 134
14.1 OVERVIEW 135
14.2 NORTH AMERICA 140
14.2.1 U.S. 149
14.2.2 CANADA 154
14.2.3 MEXICO 159
14.3 EUROPE 164
14.3.1 GERMANY 174
14.3.2 FRANCE 179
14.3.3 U.K. 184
14.3.4 ITALY 189
14.3.5 SPAIN 194
14.3.6 RUSSIA 199
14.3.7 TURKEY 204
14.3.8 NETHERLANDS 209
14.3.9 BELGIUM 214
14.3.10 SWITZERLAND 219
14.3.11 REST OF EUROPE 224
14.4 ASIA-PACIFIC 225
14.4.1 CHINA 235
14.4.2 INDIA 240
14.4.3 JAPAN 245
14.4.4 SOUTH KOREA 250
14.4.5 THAILAND 255
14.4.6 SINGAPORE 260
14.4.7 INDONESIA 265
14.4.8 MALAYSIA 270
14.4.9 PHILIPPINES 274
14.4.10 AUSTRALIA 280
14.4.11 VIETNAM 285
14.4.12 REST OF ASIA-PACIFIC 290
14.5 SOUTH AMERICA 291
14.5.1 BRAZIL 300
14.5.2 ARGENTINA 305
14.5.3 REST OF SOUTH AMERICA 310
14.6 MIDDLE EAST AND AFRICA 311
14.6.1 SOUTH AFRICA 321
14.6.2 SAUDI ARABIA 326
14.6.3 U.A.E. 331
14.6.4 EGYPT 336
14.6.5 ISRAEL 341
14.6.6 REST OF MIDDLE EAST AND AFRICA 346
15 GLOBAL COLORECTAL CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 347
15.1 COMPANY SHARE ANALYSIS: GLOBAL 347
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 348
15.3 COMPANY SHARE ANALYSIS: EUROPE 349
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 350
16 SWOT ANALYSIS 351
17 COMPANY PROFILE 352
17.1 F. HOFFMANN- LA ROCHE LTD 352
17.1.1 COMPANY SNAPSHOT 352
17.1.2 REVENUE ANALYSIS 352
17.1.3 COMPANY SHARE ANALYSIS 353
17.1.4 PRODUCT PORTFOLIO 353
17.1.5 RECENT DEVELOPMENT 353
17.2 KONINKLIJKE PHILIPS N.V. 354
17.2.1 COMPANY SNAPSHOT 354
17.2.2 REVENUE ANALYSIS 354
17.2.3 COMPANY SHARE ANALYSIS 355
17.2.4 PRODUCT PORTFOLIO 355
17.2.5 RECENT DEVELOPMENT 355
17.3 THERMO FISHER SCIENTIFIC INC. 357
17.3.1 COMPANY SNAPSHOT 357
17.3.2 REVENUE ANALYSIS 357
17.3.3 COMPANY SHARE ANALYSIS 358
17.3.4 PRODUCT PORTFOLIO 358
17.3.5 RECENT DEVELOPMENT 358
17.4 ILLUMINA, INC. 359
17.4.1 COMPANY SNAPSHOT 359
17.4.2 REVENUE ANALYSIS 359
17.4.3 COMPANY SHARE ANALYSIS 360
17.4.4 PRODUCT PORTFOLIO 360
17.4.5 RECENT DEVELOPMENT 360
17.5 QUEST DIAGNOSTICS INCORPORATED 361
17.5.1 COMPANY SNAPSHOT 361
17.5.2 REVENUE ANALYSIS 361
17.5.3 COMPANY SHARE ANALYSIS 362
17.5.4 PRODUCT PORTFOLIO 362
17.5.5 RECENT DEVELOPMENT 362
17.6 ABBOTT 363
17.6.1 COMPANY SNAPSHOT 363
17.6.2 REVENUE ANALYSIS 363
17.6.3 PRODUCT PORTFOLIO 364
17.6.4 RECENT DEVELOPMENT 364
17.7 AGILENT TECHNOLOGIES, INC. 365
17.7.1 COMPANY SNAPSHOT 365
17.7.2 REVENUE ANALYSIS 365
17.7.3 PRODUCT PORTFOLIO 366
17.7.4 RECENT DEVELOPMENT 366
17.8 BD 367
17.8.1 COMPANY SNAPSHOT 367
17.8.2 REVENUE ANALYSIS 367
17.8.3 PRODUCT PORTFOLIO 368
17.8.4 RECENT DEVELOPMENT 368
17.9 BEIJING O&D BIOTECH CO., LTD. 369
17.9.1 COMPANY SNAPSHOT 369
17.9.2 PRODUCT PORTFOLIO 369
17.9.3 RECENT DEVELOPMENT 369
17.10 BIOFIRE DIAGNOSTICS 370
17.10.1 COMPANY SNAPSHOT 370
17.10.2 REVENUE ANALYSIS 370
17.10.3 PRODUCT PORTFOLIO 371
17.10.4 RECENT DEVELOPMENT 371
17.11 BIO-RAD LABORATORIES, INC. 372
17.11.1 COMPANY SNAPSHOT 372
17.11.2 REVENUE ANALYSIS 372
17.11.3 PRODUCT PORTFOLIO 373
17.11.4 RECENT DEVELOPMENT 373
17.12 CANON MEDICAL SYSTEMS CORPORATION. 374
17.12.1 COMPANY SNAPSHOT 374
17.12.2 REVENUE ANALYSIS 374
17.12.3 PRODUCT PORTFOLIO 375
17.12.4 RECENT DEVELOPMENT 375
17.13 FONAR CORP. 376
17.13.1 COMPANY SNAPSHOT 376
17.13.2 REVENUE ANALYSIS 376
17.13.3 PRODUCT PORTFOLIO 377
17.13.4 RECENT DEVELOPMENT 377
17.14 FUJIFILM CORPORATION 378
17.14.1 COMPANY SNAPSHOT 378
17.14.2 REVENUE ANALYSIS 378
17.14.3 PRODUCT PORTFOLIO 379
17.14.4 RECENT DEVELOPMENT 379
17.15 GE HEALTHCARE. 380
17.15.1 COMPANY SNAPSHOT 380
17.15.2 REVENUE ANALYSIS 380
17.15.3 PRODUCT PORTFOLIO 381
17.15.4 RECENT DEVELOPMENT 381
17.16 HOLOGIC, INC. 382
17.16.1 COMPANY SNAPSHOT 382
17.16.2 REVENUE ANALYSIS 382
17.16.3 PRODUCT PORTFOLIO 383
17.16.4 RECENT DEVELOPMENT 383

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.